Wird geladen...
Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer
BACKGROUND: Ovarian cancer represents the most fatal type of gynecological malignancies. Unfortunately, there are still no effective targeted treatment strategies for ovarian cancer. Overexpression of CRM1 has been correlated with poor prognosis of patients with ovarian cancer. AIM: In this study, w...
Gespeichert in:
| Veröffentlicht in: | J Ovarian Res |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BioMed Central
2015
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4465006/ https://ncbi.nlm.nih.gov/pubmed/26055813 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13048-015-0166-y |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|